Nicholas Vogelzang
Hematology & Oncology · Las Vegas, NVNPI 1558361154
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Bayer at 31.1% of the total. Reporting peaked in 2019 at $189,715 and has fallen 97.8% since, to $4,136 in 2022. Among hematology & oncology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 402 payments — averaging $988.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$124K
- Sanofi$87K
- Clovis Oncology, Inc.$31K
- Merck$30K
- Pfizer$18K
- Eisai Inc.$17K
- plus $90K from 27 others
Across 1,319 payments — averaging $5972.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4.3M
- Genentech, Inc.$667K
- Astrazeneca UK Limited$587K
- Eisai Inc.$254K
- Clovis Oncology, Inc.$244K
- Seagen Inc.$224K
- plus $1.6M from 22 others
What the payments were for
- Consulting fees$176,30544%
- Speaking & faculty fees$187,54847%
- Grants$3,0001%
- Travel & lodging$24,7726%
- Food & beverage$5,4631%
- Education$2140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 104 | $123,587 |
| Sanofi | 71 | $86,514 |
| Clovis Oncology, Inc. | 37 | $31,139 |
| Merck | 37 | $30,308 |
| Pfizer | 20 | $18,469 |
| Eisai Inc. | 15 | $16,899 |
| Johnson & Johnson | 33 | $15,607 |
| Advanced Accelerator Applications | 6 | $11,993 |
| Seagen Inc. | 7 | $11,935 |
| EMD Serono, Inc. | 11 | $11,479 |
| AstraZeneca | 13 | $10,910 |
| Dendreon Pharmaceuticals LLC | 7 | $5,684 |
| F. Hoffmann-la Roche AG | 3 | $4,880 |
| Amgen | 4 | $3,603 |
| Astellas Pharma US Inc | 4 | $2,916 |
| Gilead | 3 | $2,822 |
| Myovant Sciences Inc. | 3 | $2,450 |
| Janssen Scientific Affairs, LLC | 4 | $2,194 |
| AVEO Pharmaceuticals, Inc. | 2 | $1,407 |
| Boehringer Ingelheim International GmbH | 1 | $754 |
| Helsinn Healthcare SA | 1 | $750 |
| Novartis | 1 | $218 |
| Bard Peripheral Vascular, Inc. | 1 | $150 |
| Genentech USA, Inc. | 2 | $132 |
| Olympus America Inc. | 1 | $117 |
| Exelixis Inc. | 2 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Intuitive Surgical | 2 | $85 |
| Bristol Myers Squibb | 2 | $33 |
| Lilly USA, LLC | 1 | $23 |
| Boehringer Ingelheim | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Heron Therapeutics, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$397,302 in reported general payments places this provider in the 95th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Las Vegas
- Wolfram SamlowskiLas Vegas$235K
- Oscar GoodmanLas Vegas$211K
- Aaron GoodmanLas Vegas$134K
- Anuradha ThummalaLas Vegas$128K
- Ann WiermanLas Vegas$81K
- Heather AllenLas Vegas$78K
- Holavanahalli Keshava-PrasadLas Vegas$67K
- Edgardo FaylonaLas Vegas$53K
- Khawaja JahangirLas Vegas$50K
- Clark JeanLas Vegas$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.